RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PIETRANTONIO F
Collezione AO Cuneo

Items : 5

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. in British journal of cancer / Br J Cancer. 2021 Jan;124(1):183-190. doi: 10.1038/s41416-020-01089-9. Epub 2020 Oct 7.

2021
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Falcone A; Latiano TP; Rapisardi S; Ritorto G; Masi G; Buonadonna A; Pietrantonio F; Moretto R; Zaniboni A; Caponnetto S; Ricci V; Germani MM; Lonardi S; Antoniotti C; Bergamo F; Santini D; Ermacora P; Tomasello G; Rossini D;

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Nov;139:81-89. doi: 10.1016/j.ejca.2020.08.009. Epub 2020 Sep 23.

2020
AO Cuneo

Aprile G; Grande R; Boccaccino A; Tamburini E; Fea E; Bordonaro R; Marmorino F; Buonadonna A; Pietrantonio F; Zaniboni A; Antoniotti C; Caponnetto S; Tomasello G; Cupini S; Santini D; Bergamo F; Lonardi S; Zucchelli G; Moretto R; Rossini D; Falcone A; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Borelli B; Moretto R; Lonardi S; Bonetti A; Antoniotti C; Pietrantonio F; Masi G; Burgio V; Marmorino F; Salvatore L; Rossini D; Zaniboni A; Zucchelli G; Martignetti A; Di Battista M; Pella N; Passardi A; Boccaccino A; Leone F; Colombo C; Granetto C; Vannini F; Marsico VA; Martinelli E; Antonuzzo L; Vitello S; Delliponti L; Boni L; Cremolini C; et alii...

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

2017
AO Cuneo

Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A;